Below is the message/email people are talking about. Funny
Below is the message/email people are talking about. Funny some are 'so upset'
Was totally predictable, which is why I stocked up on Tollovid. My logic was...
If the Phase II data was good, Tollovid would sell out
If Todos got a EUA, that would impact Tollovid as well
"We will see what happens with Daily in the months ahead. May be temporary - but right now as we engage with regulators we have been told this is the prudent way to go."
I read this as, regulators want assurances if they grant a EUA, Todos has enough Tollovir to supply all the hospitals.
Remember Gerald has said in the past they had plenty and the supply chain wasn't going to be an issue. Well 'plenty' is now reserved.
The only way I can read this is a very good thing for shareholders and for which ever countries that are looking into granting an EUA if that happens. With no side effects, it seems like a no brainer to me. What do you have to lose?
Gerald Commissiong @G_Commish 10h
Given increasing demand from LC users having success & need to ensure continued acute user success in face of emerging nasty descendant taking over WW, Tollovid Max is focus due to IC50 binding strength. Will see how Daily performs from clients over next weeks. Wanted to give enough time for users to stock up with supply for them/their families. We are beefing up Tollovir planning substantially. Daily is a great product. Right now as we interact with regulators for Tollovir we need to be careful - this discontinuation could end up being temporary.
Tollovid™ Daily
Is Going Away
Dear Tollovid Immunity Community,
As we grow our brand we are getting more believers in Tollovid™! The video below shows some popular names from the Celebrity Sweat® flag football game during Superbowl weekend and their endorsement of Tollovid™.
However, due to supply chain issues, we are forced to discontinue the production of Tollovid™ Daily. While supplies last, we are offering a 10% discount to our valued customers with code 10%off.
In conjunction, we currently have a limited-time promotion on Tollolvid™ Max buy 2 bottles and get 1 Tollovid™ Max FREE or take advantage of code $50off to get $50 off a bottle of Tollovid™ Max.
Thank you for your continued support of Tollovid™.
3
Todos Med Ltd. (TOMDF) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Swanson Enters the Education Arena for Nutritionists Swanson Vitamins is mixing things up again! This time, they're launching something called Swanson Vitamins Nexus Pro, aimed squarely at the registered dietitians and licensed nutritionists crowd. Starting out as the place to grab your basic vitamins, Swanson's not resting on their supplement laurels. No, siree. They've...
Continue Reading
Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...
Continue Reading
Ah, the ticking clock in the world of stock investments, where a nifty little thing called a class action lawsuit can flip your investment on its head. Right now, AST SpaceMobile (NASDAQ: ASTS) investors are staring down the barrel of one such lawsuit. With the November 13, 2026, deadline looming, it's time to sort the facts from the muck. Pins and Needles for ASTS...
Continue Reading
Kelun-Biotech's Recent Breakthrough Grab your coffee, and let's chat about something that might just change the lung cancer treatment game: Kelun-Biotech's sacituzumab tirumotecan, or sac-TMT, showing some serious promise in a Phase III trial. With numbers that could make any investor sit up a little straighter, this study has turned heads at the European Society for...
Continue Reading
Unexpected Turn of Events at Sea Now here's a gut-punch nobody saw coming. Borr Drilling Limited (NYSE and OSE: BORR) got hit hard when their Prospector 5 drilling rig went under the waves offshore Gabon. This ain't no desk job dilemma; we're talking about a real-life offshore catastrophe. It all went down on October 24, 2026, when the rig experienced a punch through...
Continue Reading
Pioneering Path with IBI3001 at ESMO 2026 Navigating through the crowded landscape of oncology trials, Innovent Biologics recently rolled out some riveting Phase 1 clinical data for their new darling, IBI3001. Top brass from Innovent took to the European Society for Medical Oncology (ESMO) Congress stage to lay bare their findings. Obviously, when you're presenting a...
Continue Reading
Axon Raises the Stakes with Body 5 Camera Boy, oh boy, Axon's dropped a bombshell with the Body 5. We're talking a colossal leap into the AI era for public safety, and if you're in the biz, you can't just shrug this one off. We're looking at 25 times the AI processing power compared to Axon's old units. That's right, I said twenty-five. Real-time situational awareness in...
Continue Reading
A Festive Transformation at CARNE Rolling into Oxnard, you're met with an unconventional dining spectacle at CARNE. It's not your average restaurant fare as they've pulled out the stops with their spirited Halloween pop-up, A Nightmare at CARNE. Channeling the eerie charm of "The Nightmare Before Christmas," this temporary transformation morphs the venue into a lively,...
Continue Reading
Beyond Premiums: Assessing Real Coverage Needs The Alaskan wilderness isn't just home to stunning views; it's also a land where insurance needs to go beyond the average cookie-cutter policy. You'd think the cheapest option would suffice, but that's where residents might trip into financial quicksand. Devery Prince, a seasoned insurance principal, sheds light on why...
Continue Reading
Young Minds Meet AI Innovation Crack open the playbook, and it's clear: young brains from across the globe are gathering in Wenzhou, Zhejiang, China, to wrangle with AI and chart the course of science toward a sustainable future. The World Young Scientist Summit 2026 isn't just a parade of speeches and accolades. Nah, it's a deep dive into where innovative minds believe...
Continue Reading
Top 5 Most Recently Viewed Articles
Unlocking the Potential of Biopesticides in Agriculture Indovinya introduces innovative solutions to enhance the use of biologically based products amidst a growing drive for sustainable crop protection. Advancements in Biopesticide Utilization The adoption of biopesticides as an alternative to traditional agrochemicals is gaining traction. However, the integration of...
Continue Reading
SCHMID Group Strengthens Market Position with New Orders In an exciting development from the SCHMID Group, a key player in the equipment manufacturing sector, the company has recently secured significant orders for Panel Level Packaging (PLP) and modified Semi-Additive (mSAP) production equipment. The orders mark a noteworthy advance as SCHMID continues to bolster its...
Continue Reading
Major Equity Financing by X4 Pharmaceuticals X4 Pharmaceuticals has made headlines recently with its announcement of a significant private equity financing round totaling $60 million. This funding is primarily geared towards advancing the company’s promising treatment for rare immune system diseases, demonstrating their commitment to improving patient outcomes. Leading...
Continue Reading
IGI Receives Fast Track Designation for ISB 2001 Results from the dose-escalation portion of the Phase 1 clinical study of ISB 2001, an innovative treatment for heavily pretreated multiple myeloma patients, will be showcased at an upcoming major oncology conference. This exciting news highlights IGI's continued progress in developing groundbreaking therapies. About ISB...
Continue Reading
Prospera Energy's Transformative Year: A Deep Dive into 2024 Financial Results In the recent strategic realignment, Prospera Energy Inc. (TSX.V: PEI, OTC: GXRFF) has successfully pivoted under new leadership, making significant strides in enhancing its production capabilities and financial outlook. This transformation was marked by key appointments, including Shubham Garg...
Continue Reading